US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using its RotaPro rotational atherectomy system at Ruijin Hospital’s Hainan Hospital (Boao research-oriented hospital) branch. This procedure marks the first clinical application of the product in China, facilitated by the “first pilot, first trial” scheme, which allowed the successful implementation of coronary intervention consumables.
First Clinical Application and Collaboration
Boston Scientific and Ruijin Hospital’s Hainan unit have agreed to establish an “innovative medical technology practice base” in Lecheng. The RotaPro rotational atherectomy system is the first product to be implemented in this base. This collaboration aims to advance the adoption of innovative medical technologies and improve patient outcomes through state-of-the-art interventions.
Future Outlook
The successful completion of the first surgery using the RotaPro system in China highlights Boston Scientific’s commitment to bringing advanced medical solutions to the Chinese market. This milestone underscores the potential of the “first pilot, first trial” scheme to accelerate the introduction of innovative medical technologies, ultimately benefiting patients and healthcare providers.-Fineline Info & Tech
